Quarterly ResultMay 11, 2026, 04:14 PM
Halozyme Announces $1B Share Buyback; Q1 Revenue +42% to $377M
AI Summary
Halozyme Therapeutics reported strong first-quarter 2026 financial results, with total revenue increasing 42% year-over-year to $376.7 million and royalty revenue up 43% to $240.7 million. The company also announced a new $1 billion share repurchase program, projecting to buy back at least $400 million in 2026. Halozyme reiterated its full-year 2026 financial guidance and highlighted several new collaboration agreements and partner product advancements, including FDA approval for VYVGART Hytrulo and positive Phase 3 data for TAK-881.
Key Highlights
- Announced new $1 billion share repurchase program through December 31, 2028.
- Projects to repurchase at least $400 million in shares during 2026.
- Q1 2026 total revenue increased 42% YoY to $376.7 million.
- Q1 2026 royalty revenue increased 43% YoY to $240.7 million.
- Q1 2026 Non-GAAP diluted EPS was $1.60, up from $1.11 in Q1 2025.
- Reiterated 2026 total revenue guidance of $1.71B - $1.81B (22%-30% growth).
- VYVGART Hytrulo received FDA approval for all generalized myasthenia gravis serotypes.
- Entered new global collaboration and license agreements with Vertex, Oruka, and GSK.